These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12830451)

  • 1. The association of nephrolithiasis with cystic fibrosis.
    Gibney EM; Goldfarb DS
    Am J Kidney Dis; 2003 Jul; 42(1):1-11. PubMed ID: 12830451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
    Hoppe B; von Unruh GE; Blank G; Rietschel E; Sidhu H; Laube N; Hesse A
    Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperoxaluria, hypocitraturia, hypomagnesiuria, and lack of intestinal colonization by Oxalobacter formigenes in a cervical spinal cord injury patient with suprapubic cystostomy, short bowel, and nephrolithiasis.
    Vaidyanathan S; von Unruh GE; Watson ID; Laube N; Willets S; Soni BL
    ScientificWorldJournal; 2006 Apr; 6():2403-10. PubMed ID: 17619709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors increasing the risk for stone formation in adult patients with cystic fibrosis.
    Terribile M; Capuano M; Cangiano G; Carnovale V; Ferrara P; Petrarulo M; Marangella M
    Nephrol Dial Transplant; 2006 Jul; 21(7):1870-5. PubMed ID: 16595587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria.
    Sidhu H; Hoppe B; Hesse A; Tenbrock K; Brömme S; Rietschel E; Peck AB
    Lancet; 1998 Sep; 352(9133):1026-9. PubMed ID: 9759746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a risk for kidney stone formation in cystic fibrosis?
    Böhles H; Michalk D
    Helv Paediatr Acta; 1982 Jun; 37(3):267-72. PubMed ID: 7118558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic fibrosis and calcium oxalate nephrolithiasis.
    Chidekel AS; Dolan TF
    Yale J Biol Med; 1996; 69(4):317-21. PubMed ID: 9273985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic risk factors for stone formation in patients with cystic fibrosis.
    Perez-Brayfield MR; Caplan D; Gatti JM; Smith EA; Kirsch AJ
    J Urol; 2002 Feb; 167(2 Pt 1):480-4. PubMed ID: 11792901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study.
    Tavasoli S; Alebouyeh M; Naji M; Shakiba Majd G; Shabani Nashtaei M; Broumandnia N; Basiri A
    BJU Int; 2020 Jan; 125(1):133-143. PubMed ID: 31145528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Milliner D; Hoppe B; Groothoff J
    Urolithiasis; 2018 Aug; 46(4):313-323. PubMed ID: 28718073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oxalobacter formigenes--characteristics and role in development of calcium oxalate urolithiasis].
    Torzewska A
    Postepy Hig Med Dosw (Online); 2013 Nov; 67():1144-53. PubMed ID: 24379255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate.
    Troxel SA; Sidhu H; Kaul P; Low RK
    J Endourol; 2003 Apr; 17(3):173-6. PubMed ID: 12803990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nephrolitiasis in a patient with cystic fibrosis].
    Orive Olondriz B; Elorz Lambarri J; Vázquez Cordero C
    An Pediatr (Barc); 2006 Aug; 65(2):154-7. PubMed ID: 16948978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: possible role in renal stone formation.
    Kumar R; Ghoshal UC; Singh G; Mittal RD
    J Gastroenterol Hepatol; 2004 Dec; 19(12):1403-9. PubMed ID: 15610315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease.
    Siva S; Barrack ER; Reddy GP; Thamilselvan V; Thamilselvan S; Menon M; Bhandari M
    BJU Int; 2009 Jan; 103(1):18-21. PubMed ID: 19021605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis?
    Hoppe B; Hesse A; Brömme S; Rietschel E; Michalk D
    Pediatr Nephrol; 1998 May; 12(4):275-9. PubMed ID: 9655356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which factors account for renal stone formation in cystic fibrosis?
    von der Heiden R; Balestra AP; Bianchetti MG; Casaulta Aebischer C; Mullis PE; Lippuner K; Jaeger P
    Clin Nephrol; 2003 Mar; 59(3):160-3. PubMed ID: 12653257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy.
    Sidhu H; Schmidt ME; Cornelius JG; Thamilselvan S; Khan SR; Hesse A; Peck AB
    J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S334-40. PubMed ID: 10541258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stone composition, metabolic profile and the presence of the gut-inhabiting bacterium Oxalobacter formigenes as risk factors for renal stone formation.
    Mittal RD; Kumar R; Mittal B; Prasad R; Bhandari M
    Med Princ Pract; 2003; 12(4):208-13. PubMed ID: 12966191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forty Years of Oxalobacter formigenes, a Gutsy Oxalate-Degrading Specialist.
    Daniel SL; Moradi L; Paiste H; Wood KD; Assimos DG; Holmes RP; Nazzal L; Hatch M; Knight J
    Appl Environ Microbiol; 2021 Aug; 87(18):e0054421. PubMed ID: 34190610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.